Uliledlimab is an antibody designed to target CD73. The development pause will also allow I-Mab to allow data from an ongoing ...

Antibodies that bind to a previously untargeted portion of the malaria parasite could lead to new monoclonal antibody treatments and vaccines for malaria.

Windward Bio has landed with a flurry of announcements, circling in a $200 million series A and offering up to $970 million ...

Marea’s Phase IIa study enrolled patients with hypertriglyceridemia—too much fat in the blood. The latest results showed the ...

A study published in Human Gene Therapy has involved the generation of a human monoclonal antibody (mAb) directed against ...

General Manager and CEO of Junshi Biosciences, Dr. Jianjun ZOU, said, “Toripalimab has made significant strides in its internationalization. As of today, toripalimab has been approved in 35 countries ...

I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision ...

Dianthus Therapeutics is advancing treatments for autoimmune diseases. Read why DNTH stock is receiving Buy ratings and price ...